Effect of iGlarLixi on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16214 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Juan P Frías und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biomea Fusion, Redwood City, California, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin Glargine, Peptides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
People with type 2 diabetes (T2D) and glycated haemoglobin (HbA1c) ≥9% may benefit from fixed‐ratio combination therapies such as iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL). Use of continuous glucose monitoring (CGM) is recommended, but data are lacking to assess the impact of iGlarLixi in individuals with HbA1c ≥9%. Materials and Methods Soli‐CGM (NCT05114590) was a 16‐week, multicentre, open‐label study evaluating the efficacy of once‐daily iGlarLixi using blinded CGM‐based metrics in insulin‐naive adults with HbA1c ≥9%–13% who were receiving ≥2 oral antihyperglycaemic agents (OADs) ± glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs). The primary outcome was the change from baseline to week 16 in percent time in range (TIR; 70–180 mg/dL). Secondary outcomes included change in mean daily blood glucose (BG), maximum postprandial glucose 4 h post‐breakfast (PPG‐4 h), and time above range (TAR; >180 mg/dL). On‐treatment hypoglycaemia was assessed.
Results
The study enrolled 124 participants (mean age, 55.6 years; HbA1c, 10.2%). Sixteen weeks of treatment with iGlarLixi improved TIR (+26.2%), mean BG (−52.5 mg/dL), maximum PPG‐4 h (−73.7 mg/dL), and TAR (−28.7%); all p < 0.001. Rates of American Diabetes Association level 1 (BG
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomea Fusion, Redwood City, California, USA.
- University of Maryland Institute for Health Computing, Bethesda, Maryland, USA.
- Division of Gerontology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
- Sanofi, Bridgewater, New Jersey, USA.
- Ividata, Paris, France.
ORCID-Profile: Juan P Frías, Alexandria Ratzki-Leewing
Förderung
- Sanofi
Zitieren
APA
Frías, J. P., Ratzki-Leewing, A., Dex, T., Meneghini, L., Rodrigues, A., & Shah, V. N. (2025). Effect of iGlarLixi on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16214
Vancouver
Frías JP, Ratzki-Leewing A, Dex T, Meneghini L, Rodrigues A, Shah VN. Effect of iGlarLixi on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16214
BibTeX
@article{Fras2025,
author = {Frías, Juan P and Ratzki-Leewing, Alexandria and Dex, Terry and Meneghini, Luigi and Rodrigues, Amélie and Shah, Viral N},
title = {Effect of iGlarLixi on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16214}
}
EUVIMED